Education
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics, Inc. (VIRX)
:VIRX
See the Price Targets and Ratings of:
VIRX Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Rodman & Renshaw
$3.5→$0.25
Hold
1150.00%
Upside
Downgraded
12/27/24
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & RenshawViracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
Leerink Partners
$3
Hold
14900.00%
Upside
Downgraded
08/15/24
Leerink Partners downgrades Viracta Therapeutics (VIRX) to Market PerformLeerink Partners analyst Andrew Berens downgraded Viracta Therapeutics (NASDAQ: VIRX) from Outperform to Market Perform with a price target of $3.00 (from $5.00).
Oppenheimer
$13→$11
Buy
54900.00%
Upside
Reiterated
05/23/24
Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Rodman & Renshaw
$3.5→$0.25
Hold
1150.00%
Upside
Downgraded
12/27/24
Viracta Therapeutics downgraded to Neutral from Buy at Rodman & RenshawViracta Therapeutics downgraded to Neutral from Buy at Rodman & Renshaw
Leerink Partners
$3
Hold
14900.00%
Upside
Downgraded
08/15/24
Leerink Partners downgrades Viracta Therapeutics (VIRX) to Market PerformLeerink Partners analyst Andrew Berens downgraded Viracta Therapeutics (NASDAQ: VIRX) from Outperform to Market Perform with a price target of $3.00 (from $5.00).
Oppenheimer
$13→$11
Buy
54900.00%
Upside
Reiterated
05/23/24
Oppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)
VIRX Analyst Recommendation Trends
Rating
May 24
Aug 24
Sep 24
Nov 24
Dec 24
Strong Buy
8
6
4
2
1
Buy
1
1
0
0
0
Hold
0
1
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
8
6
4
3
Each month's total comprises the sum of three months' worth of ratings.
VIRX Stock Forecast FAQ
What is VIRX’s average 12-month price target, according to analysts?
Based on analyst ratings, Viracta Therapeutics, Inc.’s 12-month average price target is $0.25.
What is VIRX’s upside potential, based on the analysts’ average price target?
Viracta Therapeutics, Inc. has 1150.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VIRX a Buy, Sell or Hold?
Viracta Therapeutics, Inc. has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Viracta Therapeutics, Inc.’s price target?
The average price target for Viracta Therapeutics, Inc. is $0.25. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $0.25 ,the lowest forecast is $0.25. The average price target represents 1150.00% Increase from the current price of <$0.1.
The highest analyst price target is $0.25 ,the lowest forecast is $0.25. The average price target represents 1150.00% Increase from the current price of <$0.1.
What do analysts say about Viracta Therapeutics, Inc.?
Viracta Therapeutics, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of VIRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.